Company Overview and News
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
2018-08-21 seekingalpha - 1
This is the fifth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,610.61.
GIS WBA ENB OPRF WMB SCHF JCI HSY ABBV MMM POL MO DUKH GD BAC TRV GILD MAIN CMI ENB RY BNS JNJ ITW VZ WPC ABBV MSFT ADM PFE PM PFBC IRET CTL OXLCM OXLCO TD ETN OXLCN BNS BAC MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF AFL ORI PPL
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Good morning, ladies and gentlemen, and welcome to Emera’s Q2 Analyst Conference Call. After the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time. Please note that this call is being recorded, today, August 10, 2018, at 9.00 AM Eastern Time.
EMRAF BANGN TE
2018-07-19 seekingalpha - 2
This is the fourth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,319.70.
GIS CAT WBA ENB OPRF JCI HSY ABBV MMM POL MO DUKH GD TRV MAIN CMI ENB RY BNS JNJ TROW VZ WPC ABBV MSFT ADM PFE PM PFBC SCL IRET CTL OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL CBL
The future of Ontario's partially privatized utility is again uncertain after political intervention prompted the resignation of the company's board 16 years after another mass departure.
ACLTF EMRAF H FTS AVA HRNNF
No investment occurs within a vacuum, and a 40,000 ft evaluation of financial goals, investment risk tolerance, and portfolio construction should be conducted on an ongoing basis.
SWX SOJA ETR VVC SO ATGFF EMRAF SCG WGL FE
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG DUKH GD TRV MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA INTC TD IBM RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL
As a very slow growth sector, the forward PEG ratios for utilities are comparatively obscenely high but are still a valuable tool.
SWX NI SOJA OGS ATO DTJ NRGEO ATGFF AEP BKHU CMS ED EXC NEE SO DUKH LNT WTR DUK BKH ETR NRG XEL EMRAF CMSA DTW SRE DTV CNP PPL DTY FE
Last Tuesday, I published my top 5 US dividend growth stocks. Today, I'm coming back with my Canadian picks. Believe it or not, there is more than banks and telecoms on the market for income-seeking investors! As a long-term dividend blogger, I'm often asked what are my favorite dividend growth stocks. It's hard to make a short list as there are so many great companies out there. Based on my 7 investing principles, I've selected 5 I really like right now.
ANCUF CDNTF EMRAF ATD.A AMZN ANCTF ATD.B CDNAF ADWPF BIP TE
In this article, we'll review all utilities in Canada that have increased their dividend for 5 or more years in a row and apply a dividend growth screen to try and find the best high-quality utility companies for further consideration. Turns out there was only one company that passed all of the criteria, but there are still a few other companies that are worthy of your consideration.
ACLTF CNUTF FTS EMRAF RNW VALU FTS TRI BIP CDUAF TRSWF CU
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET